Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Reminyl · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Galantamine | EXPERIMENTAL | Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited |
| Reminyl | ACTIVE_COMPARATOR | Reminyl 4 mg tablets of Janssen Pharmaceutical Products |
| Name | Type | Description |
|---|---|---|
| Reminyl | DRUG | Galantamine Hydrobromide Tablets 4 mg |
Inclusion Criteria: Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified: * Healthy adult male volunteers, 18-55 years of age; * Weighing at least 60 kg and within 15% of their ideal weights (Table of "Des...
Reminyl is a small molecule drug being developed by Dr. Reddy's Laboratories Ltd. It is currently in Phase 1 clinical development for use in fed and fasting conditions. The drug is being studied in healthy volunteers to assess its effects under these different dietary states.
Reminyl is developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company traded on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials to evaluate the drug's properties in healthy volunteers.
Reminyl is in Phase 1 clinical development. It has completed one trial with a total enrollment of 28 participants. The drug is still investigational and has not been approved for any medical use.
Reminyl has been studied in two completed Phase 1 clinical trials. NCT01372280 evaluated the drug under fasting conditions in 28 healthy male volunteers, and NCT01372306 evaluated it under fed conditions in 24 healthy male volunteers. Both trials were active-controlled and not double-blinded.
Reminyl is a brand name for the drug galantamine. The clinical trials conducted by Dr. Reddy's Laboratories Ltd are titled as galantamine bioequivalence studies, indicating that Reminyl contains galantamine as its active ingredient.